Health
Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-Clinical Studies – HospiMedica
Johnson & Johnson’s (New Brunswick, NJ, USA) lead vaccine candidate has successfully protected monkeys against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies.
Johnson & Johnsons (New Brunswick, NJ, USA) lead vaccine candidate has successfully protected monkeys against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies.The companys investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by neutralizing antibodies, successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates…
-
General23 hours agoNewcastle Jets defeat semi-professional Heidelberg United 3-1 to lift first Australia Cup
-
Noosa News9 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
Noosa News15 hours agoMedia adviser launches $4m malicious prosecution claim over kidnap case
-
General12 hours agoEnglish springer spaniels Kelly and Milo helping fight dieback in Western Australia